Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

NMPA (then CFDA)Regulator guidanceBioequivalenceMedicinesMedium confidenceLast verified October 5, 2026

NMPA Notice 2016 No. 61, Annex 3

Technical guideline for human bioequivalence studies of chemical generic drugs with pharmacokinetic endpoints

Current edition

2016 (notice dated 18 March 2016)

About this standard

General principles for bioequivalence studies of generic chemical drugs that use pharmacokinetic parameters as endpoints: design, subjects, reference product, fed and fasting studies, parameters, statistics and special cases.

Recognition by market

Whether the market recognizes, harmonizes or adopts this standard, and which edition it accepts

No market listing is published yet.

Testing requirements that cite it

Open the market page and its pathway pages for the full requirement, protocol and report content

Related standards: JP guideline for bioequivalence studies of generic products, MHRA comparator product guidance, CPMP/EWP/QWP/1401/98 Rev 1, JP BE guideline, formulation changes (oral solid), FDA BE guidance for ANDAs (PK endpoints), NMPA Notice 2016 No. 61, Annex 1, HC comparative bioavailability conduct guidance, HC comparative bioavailability standards, HC foreign-sourced reference product guidance, HC proportional formulations policy, M9, M13A. See all standards.

Not legal or regulatory advice. Check the current official rules before you act. Parts of the approvals data are official open data reused under open licences. Data sources.

LinkedInLinkedInXXYouTubeYouTube